Germany Artificial Organs and Bionics Market Size

Germany Artificial Organs & Bionic Implants Market Analysis

The German artificial organs and bionics market is expected to register a CAGR of 5% during the forecast period.

The COVID-19 pandemic had an unprecedented public health threat that harmed communities, industries, enterprises, and people throughout Germany. COVID-19 hampered the supply and manufacture of artificial organs and bionics. According to the study published by Colégio Brasileiro de Cirurgiões in May 2021, in Germany, there were no appreciable changes in the number of patients on the lung transplant waiting list, the overall number of organ donors, or the death rate on the lung transplant waiting list in the first five months of 2020. Moreover, a study published in Transplantation in July 2022 revealed a slight decline in transplant rates in Germany along with higher death rates. As a result, there were no changes in the organ transplant waiting list. However, there was a slight decline in transplant activity in the country hampered the growth of the studied market. The market recovery over the last two years has been driven by the high prevalence of diseases and product launches by market players.

The major factors responsible for the growth of the artificial organs and bionics market include the scarcity of donor organs for organ transplantation and technological advancements. The lack of availability of potential organs to transplant has been a major issue. As reported by the IRODaT in July 2022, Germany's organ donation rate remained stubbornly low in 2020. More than 9,000 people are already on the organ waiting list. Germany's organ donation rate is over three times lower than the United States and more than four times lower than that of world leader Spain, with 11.5 donors per million people. Bionics and artificial organs can cater to the needs of those in need of organ transplantations and replacements. They can replicate the function of damaged organs.

Moreover, various organic and inorganic strategies adopted by key market players are expected to boost market growth during the forecast period. For instance, in July 2021, Ottobock planned to prepare for a huge stock market IPO in 2022 that may value the German manufacturer of prosthetic limbs at more than EUR 5 billion (USD 5.9 billion). Additionally, in November 2021, Ottobock acquired 100% of the shares of suitX, a US-based company spun out of the Robotics and Human Engineering Lab at the University of California, Berkeley, which specializes in the research and development of occupational and medical exoskeletons. Ottobock and suitX are combining their expertise and products to take the exoskeleton market to a new level and to foster the worldwide adoption of exoskeletons.

However, other factors, such as the high cost of the procedure, the risk of compatibility issues, and malfunctions are expected to impede the market growth.